Allogene Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Employees: 233

Market Cap: $560.4M

Website: http://www.allogene.com

Introduction: Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Clinical Trials

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Genetic: cemacabtagene ansegedleucel
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-07-15

Last Posted Date: 2024-11-29

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 250

Registration Number: NCT06500273

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Louisville Health Brown Cancer Center, Louisville, Kentucky, United States

and more 25 locations

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Large B Cell Lymphoma

Interventions: Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Genetic: ALLO-501A

First Posted Date: 2023-02-06

Last Posted Date: 2024-05-31

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 70

Registration Number: NCT05714345

Locations: 🇧🇪
Universitair Ziekenhuis Brussel, Brussel, Belgium
🇺🇸
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-605
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-08-11

Last Posted Date: 2024-06-28

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 6

Registration Number: NCT05000450

Locations: 🇺🇸
St. David's South Austin Medical Center, Austin, Texas, United States
🇺🇸
Sarah Cannon/Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Interventions: Genetic: ALLO-316
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-01-06

Last Posted Date: 2024-11-01

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 120

Registration Number: NCT04696731

Locations: 🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸
Georgetown University Hospital, Washington, District of Columbia, United States

and more 7 locations

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Phase 1

Recruiting

Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions: Genetic: ALLO-501A
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2020-06-04

Last Posted Date: 2024-06-06

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 160

Registration Number: NCT04416984

Locations: 🇺🇸
Northside Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 36 locations

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-715
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Nirogacestat

First Posted Date: 2019-09-18

Last Posted Date: 2023-08-14

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 132

Registration Number: NCT04093596

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 8 locations

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Large B Cell Lymphoma
Relapsed/Refractory Follicular Lymphoma

Interventions: Genetic: ALLO-501
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-06

Last Posted Date: 2023-12-01

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 74

Registration Number: NCT03939026

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
St. Davids South Austin Medical Center, Austin, Texas, United States

and more 4 locations

Home Terms & Conditions Privacy Policy